| _version_ |
1797287150135279616
|
| collection |
DOAJ
|
| first_indexed |
2024-03-07T18:28:47Z
|
| format |
Article
|
| id |
doaj.art-341da9e072234a9e8d79a12ce4b67558
|
| institution |
Directory Open Access Journal
|
| issn |
2572-9241
|
| language |
English
|
| last_indexed |
2024-03-07T18:28:47Z
|
| publishDate |
2018-10-01
|
| publisher |
Wiley
|
| record_format |
Article
|
| series |
HemaSphere
|
| spelling |
doaj.art-341da9e072234a9e8d79a12ce4b675582024-03-02T06:41:25ZengWileyHemaSphere2572-92412018-10-012293010.1097/01.HS9.0000547919.69672.2a201810003-00076P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDYhttp://journals.lww.com/10.1097/01.HS9.0000547919.69672.2a
|
| spellingShingle |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
HemaSphere
|
| title |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
|
| title_full |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
|
| title_fullStr |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
|
| title_full_unstemmed |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
|
| title_short |
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
|
| title_sort |
p072 0038 frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression free survival vs chemotherapy alone in patients with stage iii or iv hodgkin lymphoma phase 3 echelon 1 study
|
| url |
http://journals.lww.com/10.1097/01.HS9.0000547919.69672.2a
|